Astellas wins Japanese approval for Xtandi; Ukraine conflict dents Stada forecasts;

@FiercePharma: Just out: today's full issue of FiercePharmaMarketing. More | Follow @FiercePharma

@TracyStaton: Anti-inflammatories rule! Top 3 best-selling drugs last year = Humira, Enbrel + Remicade. Report | Follow @TracyStaton

@EricPFierce: AmerisourceBergen global expansion continues with $100M deal for a 20% stake in Brazil's Profarma. Article | Follow @EricPFierce

@CarlyHFierce: AstraZeneca, Pfizer say direct-delivery programs can win with patients. Story | Follow @CarlyHFierce

> Baxter International ($BAX) has cut shipments of emergency-room staple nitroglycerin, putting it in short supply. More (sub. req.)

> Astellas has won marketing approval in Japan for its prostate cancer treatment Xtandi. Release

> Medical patch maker Corium has updated its plans to go public, saying its IPO could raise up to $76 million. More

> Japanese pharma Dainippon Sumitomo Pharma (DSP) has won approval to market its Latuda as a treatment for schizophrenia in adults. Report

> Stada sank the most in more than two years after announcing its sales and profit would be less than forecast thanks to the Russia-Ukraine conflict. More

> The FDA's Janet Woodcock is disputing research published last year that found impurities in several generic heart drugs made overseas. More

Medical Device News

@FierceMedDev: More legal action is in the mix against Intuitive over its robotic surgical device. Story | Follow @FierceMedDev

@MarkHFierce: The latest FierceDiagnostics is ready for you, featuring details on an IPO, cancer Dx and Alzheimer's biomarkers. Report | Follow @MarkHFierce

@MichaelGFierce: Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Tiny recorder helps parents communicate with children, and could spur brain development. Article | Follow @EmilyWFierce

> Did J&J intentionally destroy documents relevant to patients' vaginal mesh lawsuits? Story

> GE Healthcare will supply cancer Dx tools in new Indian care clinics. News

Biotech News

@FierceBiotech: Startup scPharmaceuticals snags $16M for self-dosed injectables. Read | Follow @FierceBiotech

@JohnCFierce: Fierce readies a new weekly report on the European biotech scene. Details | Follow @JohnCFierce

@DamianFierce: Sanofi bets big on dengue with eyes on a blockbuster. More | Follow @DamianFierce

@EmilyMFierce: Most read at FierceBiotechResearch.com yesterday: Amylin diabetes drug improves learning, memory in Alzheimer's mice. Story | Follow @EmilyMFierce

> With FDA decision looming, GlaxoSmithKline nails EU OK for diabetes drug albiglutide. News

> Insmed faces another setback as lead therapy flunks PhII lung study. Story

Drug Delivery News

> Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. News

> Nasal spray for depression offers minimally invasive treatment option. Story

> FDA accepts Avanir's inhaled migraine treatment application. News

> Small, drug-releasing battery could dissolve completely over time. Article

> Clumps of gold nanoparticles retain heat or drugs to kill cancer cells. Story

> Alexza secures $45 million from investors based on U.S. Adasuve sales. Brief

Diagnostics News

> Ariosa Diagnostics mulls an IPO worth up to $69M. News

> Foundation Medicine seeks up to $150M to keep its cancer Dx growth engine running. Story

> CTC levels could provide a prostate cancer survival clue. Article

> Mobile app could offer inexpensive Dx in developing world. Story

> Two Alzheimer's biomarker studies spur hope for earlier-stage diagnosis. Story

> Four new biomarkers may enable an earlier stomach cancer diagnosis. Brief

Pharma Marketing News

> ASCO plans cost-benefit scorecard for cancer meds as prices grow 'unsustainable.' Story

> Pharma is a 'design industry,' expert says. So why don't all Big Pharmas have CDOs? Article

> Astellas presents The Bladder, animated pitch-organ for overactive-bladder med Myrbetriq. Story

> AstraZeneca, Pfizer say direct-delivery programs can win with patients. Article

> Great expectations: Patients think pharma owes them apps, rewards, and more. Piece

> AstraZeneca, Sanofi tap mobile providers for patient-monitoring services. Brief

And Finally... Human growth hormone--antiaging elixir or cancer and early death risk? It could be both, scientists say. Report (sub. req.)

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.